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Introduction: 
 
• (1.1) Definition and Epidemiology: 
Cholangiocarcinoma (CC) refers to all tumors originating from bile duct 
epithelial cells. Adenocarcinoma represents more than 90% of 
Cholangiocarcinoma. Distinguished by its anatomical location, CCs are classified 
into intrahepatic, perihilar, or distal. Intrahepatic cholangiocarcinoma (IC) is 
located within the liver parenchyma and subdivided according to its growth 
pattern into: mass forming; peri-ductal and intra-ductal growing.1-3 Mass forming 
subtype is the most common and presents as a solid nodule within the liver 
parenchyma. The intraductal subtype is the least common and least aggressive. 
Periductal infiltrating IC invade the liver parenchyma along portal structures and 
metastasize to hilar lymph nodes. In a Japanese series, a combined mass-
forming–periductal-infiltrating tumor is an aggressive subtype. In western 
populations, this observation has not been reported.4-8  
In a population-based data from United States; the incidence of IC is 1.5 
times in men as in women with an average age of diagnosis of 50 years.9 Despite 
its rarity, IC accounts for 20% to 25% of all CC and represents the second most 
frequent primary liver tumor after Hepatocellular carcinoma (HCC). The 
incidence of IC is increasing in western population with a reported incidence 2.1 
per 100,000.10-12  
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Reports of annual increase of mortality rates have been published from Italian, 
German, Korean databases and globally reported by World Health Organization’s 
database. 13-17 It is not yet well understood whether this increase due to recent 
increase in Hepatitis C incidence, due to increased tumor detection or attributable 
to recent changes in its staging system. However, no significant increase is 
reported in the proportion of smaller detected tumors. Therefore, there’s no strong 
evidence to prove the correlation between the rise in incidence and early tumor 
detection.18,19  
• (1.2) Predisposing Factors 
 Unfortunately, studies examining potential risk factors often do not 
differentiate between CC subtypes.20,21 Although in most of diagnosed IC patients 
have not reported associated risk factors. Nevertheless, some case-controlled 
studies have reported Hepatitis B, C viral infection and liver cirrhosis as a 
significant risk factors for IC. Indeed, the impact and incidence of these risk 
factors is higher in HCC than for IC.22-24 Less well-established local risk factors 
for IC include chronic biliary inflammation as in hepatobiliary flukes, primary 
sclerosing cholangitis, biliary tract cysts. Other general risk factors include 
diabetes, obesity, alcohol, tobacco smoking. Further studies are needed to verify 
the risk factors are potentially associated with IC. 25  
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• (1.3) Staging and Prognostic Factors 
In the 6th edition of American Joint committee on Cancer (AJCC), the 
staging system for IC was identical to Hepatocellular Carcinoma (HCC). This 
staging system did not include any clinical or pathological predictive factors 
which are related to IC exclusively. 26 
The first independent staging system for IC was published on 2010 by the 
AJCC in its revised 7th edition.  Tumor number, vascular invasion, periductal 
invasion and lymph node metastasis status were identified as the main prognostic 
factors which influence survival after liver resection. Nathan et al have identified 
these factors as independent predictors of survival and proposed the new staging 
system in their retrospective cohort study using the Surveillance, Epidemiology, 
and End Results (SEER) database.  As reported in his study, tumor size per se has 
no impact on survival. 27-28 Authors have reported that AJCC 7th edition can 
accurately discriminate outcome of patients with resectable IC and can predict 
the survival according to TNM staging system. 29 
Recently, the AJCC has released the 8th edition in which tumor size and 
number, vascular invasion, lymph node involvement and invasion of visceral 
peritoneum were major prognostic factors for IC. Periductal invasion has not been 
recognized a as a prognostic factor in the 8th edition. Tumor size was independent 
prognostic factor in absence of Lymph-vascular involvement. 30  
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The 8th edition did not show any significant advantage over 7th edition in 
overall prognostic discrimination except for stage III and T3 lesions.31 
• (1.4) Clinical presentation and diagnosis 
Most of IC are asymptomatic in their early stages. Patients with IC are 
more likely to present with non-specific symptoms such as vague abdominal pain 
or discomfort. In advanced stages, IC is accompanied by weight loss, 
hepatomegaly and may present with a palpable abdominal mass. Biliary 
obstruction related symptoms are less frequent to occur in IC as in extrahepatic 
cholangiocarcinoma.32  
IC may be incidentally diagnosed by cross-sectional imaging performed 
for other reason e.g. ultrasonography (US) or computed tomography (CT). On 
US, IC appears as a hypoechoic mass and possibly peripheral ductal dilatation. 
Dynamic CT scanning describes the location and extension of the lesion, lymph-
vascular involvement and can help to distinguish between IC and HCC. Magnetic 
Resonant Cholangio-Pancreatography (MRCP) has higher sensitivity, specifity 
and better diagnostic accuracy than any imaging modality.33-35 Invasive 
cholangiography such as Endoscopic Retrograde Cholangio-Pancreatography 
(ERCP) or Percutaneous Cholangiography (PTC) are recommended when 
palliative biliary decompensation is required.36 Positron emission tomography 
(PET) is of limited role in diagnosis when CT or MRI imaging has been 
performed for diagnosis of IC. 37 
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Liver core biopsy is recommended for definitive diagnosis of IC patients 
undergoing systemic chemotherapy, radiation therapy or for enrollment in a 
therapeutic clinical trial. For patients undergoing resection, liver biopsy is not 
recommended due to risk of tumor seedings. 38  
 Tumor markers as Carbohydrate Antigen (CA) 19.9 and 
carcinoembryonic antigen (CEA) are of limited use in the clinical practice due to 
low sensitivity and specifity. They may be of diagnostic value as some studies 
have shown that CA 19-9 values greater than 100 U/ml were associated with 
worse recurrence-free survival after surgical resection.39 
• (1.5) Treatment  
Complete surgical resection (SR) is the gold standard treatment with 
potential curative intent for patients with IC. The National Comprehensive 
Cancer network (NCCN) guidelines has stratified non-metastatic IC patients into 
potential resectable and non-resectable cases.  
For accurate staging, it highly recommends staging laparoscopy and 
regional lymphadenectomy.41 Curative resection referred to achieving negative 
margin (R0) with adequate function future remnant liver volume (FLR). Ribero 
et al from the Italian Intrahepatic Cholangiocarcinoma Study group reported that 
margin status is a significant predictor of survival and recurrence. 42,43 R0 
resection should be the goal of the surgical procedure regardless the local 
extension of the disease as it provides a better chance for prolonged survival, 
particularly in lymph node negative patients (N0). 44-46    
 9  
However, curative surgical resection remains challenging not only in terms 
of achieving negative margin but also to keep a sufficient FLR to avoid post-
hepatectomy liver failure (PHLF). Plenty high volume Hepatobiliary centers have 
reported that, extended hepatectomy with/ without biliary reconstruction were 
performed in majority of IC cases due to extension, location or multifocality of 
the disease.45,47-50 
In order to avoid PHLF due to small FLR after resection, different vascular 
manipulations have been performed in order to induce residual liver parenchyma 
hypertrophy. The first attempt attributed to Makuuchi in 1980, who invented the 
portal vein embolization (PVE) of the right portal vein branch to induce left lobe 
hypertrophy. 51 PVE could induce up to 70% increase in the standardized FLR 
within 6 weeks duration as reported by Kianmanesh et al.52 The second attempt 
was developed by surgeons at Hospital Paul Brousse in Paris, France who have 
introduced the 1st “two-stage hepatectomy” concept in which sequential 
operations performed to stepwise resect multiple tumors allowing the liver to 
regenerate between procedures.53 Daniel Jaeck  from Strasbourg, France has 
utilized these techniques and routinely performed PVE after initial excision of 
left liver lobe tumors to achieve clean left lobe and afterwards performed a safe 
right or extended right hemihepatectomy. 54 This technique has been rapidly 
adopted by many surgeons but instead to PVE, portal vein ligation was performed 
alternatively in the first stage operation along with excision of left lobe tumors. 
Few weeks later, an extended right hepatectomy was performed. 
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 Data have showed that PVL induce similar or better left lobe hypertrophy 
response. 55-57 However, the need for long intervals between interventions (6–12 
weeks) allows progression of the disease that might postpone stage-2 
hepatectomy. About 19 –33% of patients who undergo conventional 2 stage 
hepatectomy fail to undergo the second stage operation due to insufficient 
hypertrophy and/or tumor progression.58-60 
In 2012, Schnitzbauer et al has introduced the initial novel experience of a 
2-stage hepatectomy technique which was performed in 25 patients from 5 
hepatobiliary German Centers. The novelty of this technique attributed to the in-
situ split in the stage-1 hepatectomy. This approach combines liver partition (in-
situ spilt) in the first operation with PVL followed by a second operation to 
remove the diseased part of the liver. The preliminary results, in terms of 
accelerated (6-20 days) FLR hypertrophy and R0 resection for classically 
described marginal non-resectable disease, were surprisingly promising.61 Later 
on, this technique was widely practiced among hepatobiliary surgeons’ 
community and known as “Associating Liver Partition and Portal Vein Ligation 
for Staged Hepatectomy.” with the acronym ALPPS.62-64  
Despite of its encouraging primary results, ALPPS procedure remains 
highly controversial. Some understandable concerns were raised due to high rates 
of morbidity and in-hospital mortality compared to conventional major 
hepatectomies. Authors recommended that ALPPS procedure should be 
performed strictly in trials and registries, namely in primary liver tumors. Others 
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reported that low morbidity and negligible mortality could be achieved with more 
strict risk adjustments and in colorectal liver metastasis patients. 65-67  
At present, the mid and long-term outcome of ALPPS procedures 
performed for IC patients remain unverified. No studies yet have been performed 
to investigate its long-term survival and oncological outcomes in comparison to 
the palliative chemotherapy. Therefore, we sought to retrospectively evaluate the 
therapeutic benefit of ALPPS procedure performed for Intrahepatic 
Cholangiocarcinoma patients with special emphasis on post-operative morbidity 
and early mortality. 
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2. Aim of Work 
To evaluate the long-term therapeutic benefit of ALPPS procedure for 
Intrahepatic cholangiocarcinoma in terms of oncological outcome and overall 
survival, in comparison to palliative chemotherapy with special emphasis on 
morbidity and early mortality. 
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3. Patients and Methods   
• (3.1) Study Design: 
This is a longitudinal cohort multicenter study with prospective evaluation of 
long-term outcome of ALPPS procedure for IC patients in comparison to 
palliative chemotherapy (CTH). 
• (3.2) Study population and Data collection: 
a) ALPPS patients: 
All adult patients with primary diagnosis of IC underwent ALLPS 
procedure during the period from July/2011 till January/2018, with either data 
recorded in ALPPS registry or from some other hepatobiliary centers not 
recorded in the registry, were included in the study. Patients with unknown 
survival or did not complete the 2nd stage hepatectomy were excluded from the 
survival analysis.  
The International ALPPS Registry was set up in 2012 and is coordinately 
maintained by the Department of Surgery, University of Zurich, Switzerland, 
approved by the Cantonal Ethics Committee of Zurich (KEK 2013-0326) and is 
registered at ClinicalTrials.gov (NCT01924741). The registry serves as a data 
platform to prospectively collect the worldwide experience of this procedure 
using a web-based data capture system secuTrial (Interactive System, Berlin, 
Germany). Registry data were exported for the current analysis starting from 
November, 2017 till July, 2018.  
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About 25 hepatopancreatobiliary centers have participated in this study. Clinical 
investigators or directors of these units were invited to participate via e-mails or 
personal contacts. The participant centers are: 
§ Germany: University Hospital-Aachen, University Hospital-Tübingen; 
University Medical Center-Hamburg, University Hospital-Jena; University 
Hospital-Cologne; University medical center-Frankfurt; Neuperlach clinic-
Munch; medical center-Barmbek; medical center-Karlsruhe. 
§ Italy: Padua University Hospital, San Raffaele Hospital-Milano, Polytechnic 
University of Marche-Ancona. 
§ Switzerland: University Hospital-Zurich 
§ China: Sun Yat-sen Memorial University Hospital 
§ Argentina: Hospital Italiano de Buenos Aires 
§ Turkey: Ankara University Hospital  
§ Czech Republic: Institute for Clinical and Experimental Medicine-Prague. 
§ Spain: Virgen de la Arrixaca University Hospital, Madrid Sanchinarro 
University Hospital. 
§ Sweden: Linköping University Hospital 
§ Canada: Western University Hospital in London-Ontario 
§ Belgium: Gent University Hospital. 
§ France: Hospital Paul Brousse-Villejuif 
§ Japan: Matsuyama Red Cross Hospital 
§ Russia: Scientific Center of FMBA-Moscow. 
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b) CTH patients: 
All adult patients in the Surveillance, Epidemiology, and End Results (SEER) 
database diagnosed with primary IC who received CTH as a palliative treatment 
and didn’t undergo surgical resection but between January.2010 till 
December.2013 were included.  Patients with unknown survival or non-
pathology evidence were excluded from the study. 
The SEER database is issued by the National Cancer Institute (NCI) 
(www.seer.cancer.gov) in the United States and collects data from 18 population-
based cancer registries covering approximately 28% of the US cancer population. 
The SEER*Stat statistical software, version 8.3.2 was used in this study. We 
would like to underline that SEER database administration does not provide 
chemotherapy data automatically. A special request was submitted to retrieve 
these data independently. The chemotherapy data represented as (Yes, 
No/unknown). The chemotherapy regimens are not described in detail as regard 
CTH regime, response rate, recurrence rate or associate complications 
• (3.3) Variable definitions: 
a) ALPPS Patients: 
Data on patient demographics, comorbidities, liver parenchyma (normal 
vs. diseased: histology evidence of liver steatosis, fibrosis or cirrhosis), 
volumetric data, procedure details, tumor pathology, complications, follow up, 
survival, and recurrence were provided by ALPPS registry and participating 
centers and were exported into a Microsoft Excel table. 
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b) CTH Patients:  
Patients with a primary IC were identified according to the International 
Classification of Diseases for Oncology, 3rd Edition, ICD-O-3/WHO 2008. TNM 
staging was derived from the 7th editions of the AJCC Staging System. The 
SEER Program Coding and Staging Manual (2015) was used to select the study 
population, i.e. the primary site code “C22.1” for the intrahepatic bile duct, ICD-
O-3 histology/behavior code “8160/3” for cholangiocarcinoma. The codes for 
tumor size, extension, multifocality, and vascular invasion, the data on lymph 
node metastases, were interpreted using the Collaborative Stage data set. 
(http://web2.facs.org/cstage0205/liver/Liverschema.html) 
• (3.4) Outcome assessment 
The main outcome was mortality which is subclassified into early mortality 
(90-day mortality), and disease related or non-related mortality. Overall survival 
(OS) was defined from the date of the 2nd stage hepatectomy until death or 
August 2018. Complications were identified according to liver surgery specific 
clinical endpoints (CEP). The five elements of CEP beside mortality are post 
hepatectomy liver failure (PHLF), ascites, biliary complications, infection and 
post hepatectomy haemorrhage (PHH).68 Complications were presented 
according to the definitions of the International Study Group of Liver Surgery 
(ISGLS) and the Dindo-Clavien classification.69-72 We defined severe 
complications as a Dindo-Clavien grade IIIb or greater with in-hospital mortality 
included.  
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Oncological results, which are sub-classified short term represented by free 
tumor resection margin (R0) and mid, long-term which represented by recurrence 
rate, risk of recurrence and time to recurrence. Time to recurrence was   
determined from the hepatectomy until recurrence at any site (hepatic or extra-
hepatic). Long-term outcomes of all patients were retrospectively analyzed. 
Further outcome parameters included volumetry study which is represented by 
FLR and FLR over body weight (FLR/BW). The median values of FLR/BW after 
stage-1 and stage-2 hepatectomies were utilized as a cut-off values for logistic 
regression analyses. We would like to underline that, the represented percentages 
in the result section exclude the missing values.   
• (3.5) Statistical analysis 
Continuous variables are expressed as median (minimum-maximum) and 
were analyzed by the Mann-Whitney U test. Categorical-nominal variables are 
presented as a number (percentage) and were analyzed by the C2 or Fisher’s exact 
tests, as appropriate. For the ALPPS group, Uni- and multivariate logistic 
regression analyses were performed to verify risk factors for severe complications 
and univariate logistic regression for 90-day mortality cases. 
The Kaplan Meier method was utilized to calculate overall survival and 
recurrence, and the Log-rank test was used to assess difference between curves. 
Cox proportional hazard regression was performed to evaluate risk factors 
associated with prognosis. Variables with p<0.1 in the univariate analysis were 
further included in the multivariate Cox proportional hazards regression analysis 
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with a stepwise forward conditional selection. Based on the propensity score 
(PS), one-to-one nearest neighbor matching with replacement was adopted to 
overcome selection bias and minimized difference between CTH group and 
ALPPS group. The propensity score calculated by a logistic regression model 
represent the probability of each patients being assigned to each treatment. The 
variables included in this model were: Age, Gender, Stage, N status. The use of 
PS analysis along with multivariate cox proportional hazard modeling have 
proved to be beneficial to adjust for confounders in small datasets in terms of be 
less biased, more robust, and more precise than standard multivariable methods. 
The number of enrolled patients in the propensity score analysis might be 
minimized according to missing values and to achieve patients’ matching. Two-
tailed p<0.05 values were considered statistically significance and all statistical 
calculations were performed using SPSS version 21.0 (Chicago, IL).  
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4. Results: 
• 4.1 Demographics and Patients’ Characteristics: 
a) ALPPS group 
Out of 86 patients undergoing ALPPS procedure between July/2011 till 
January/2018, 84 patients have completed the 2nd stage hepatectomy. Two 
patients didn’t undergo 2nd stage hepatectomy due to insufficient FLR. The 
median age was 65 years old ranging from 35 to 80 and around 47.6% above 65 
years (n=40). Female patients represented 59 % (n = 50). (Table.1) 
The median value of body mass index (BMI) was 25.3 ranging from 16.3 to 
38.3. Diabetes mellitus presented in 12% of the patients, other comorbidities e.g. 
hypertension or obstructive lung disease was diagnosed in 14 %. Neoadjuvant 
CTH was given in 7 patients. Radiological interventions were performed in 5% 
of the patients prior to ALPPS. Only one patient underwent major abdominal 
surgery prior to ALPPS procedure. (Table.2) 
By preoperative radiological evaluation, 73.2% of the patients had a single 
lesion centrally located (n=60); 19.5% of the patients had multiple tumors located 
in right liver lobe required extended right hepatectomy (n=16) and 7% of the 
patients had bilobar tumors required clearance of FLR and right or extended right 
hepatectomy (n=6). According to surgeons’ assessment, 97% of the cases had 
insufficient FLR (n=81). (Table.2) 
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b) CTH group 
 In SEER database, 484 patients were diagnosed with primary IC. 453 with 
pathological diagnostic confirmation of IC. Around 46% above 65 years (n=208). 
Female patients represented 55.4 % (n = 251). Based on the AJCC 7th edition, 
Stage I represents 21.2% (n=96), stage II represents 27.4% (n=124). Stage III and 
IV a represent 35.4% (n= 160). Unknown staging was reported in 16% of the 
patients (n=73). Majority of CTH group patients (44.6%) presented with T2 
lesions (n=202). Regional lymph node metastasis was reported in 25.2% (n=114). 
90-day mortality after CTH treatment was reported in 13.9% (n=63). Overall 
mortality was reported in 64.9% (n= 294). Other demographics and clinico-
pathological characteristics are presented in table 1. 
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Table no.1: Patients’ characteristics and demographic data 
Variable Categorization CTH Group (453) ALPPS Group (84) 
Age continuous 64 (26-85) 65 (35-80) 
<65 244 - 53,9% 44 - 52,4% 
>65 208 - 46,1% 40 - 47,6 
Gender F 251- 55,4% 50 - 59,2% 
M 202 - 44,6% 34 - 40,8% 
Grade G1 16 - 3,5% 6 - 7,1% 
G2 63 - 13,9% 43 - 51,2% 
G3 84 - 18,5% 28 - 33,3% 
Missing value 290 - 64,1% 7 - 8,4% 
Stage I 96 - 21,2% 6 - 7,1% 
II 124 - 27,4% 33 - 39,3% 
III 27 - 6% 7 - 8,4% 
IVa 133 - 29,4% 34 - 40,5% 
Missing value 73 - 16% 4 - 4,7% 
T T1 129 - 25,8% 9 - 10,4% 
T2 202 - 44,6% 55 - 65,5% 
T3 46 - 10,1% 15 - 17,9% 
T4 32 - 9,8% 1 - 1,5% 
TX 44 - 9,7% 4 - 4,7% 
N N0 272 - 60% 48 - 57,1% 
N1 114 - 25,2% 33 - 39,3% 
NX 67 - 14,8% 3 - 3,6% 
M M0 453 - 100% 81 - 100% 
M1 0 - 0% 0 - 0% 
MX 67 - 14,8% 3 - 3,6% 
Size continuous 70 (5-200) 85 (6-260) 
90-day Mortality N 390 - 86,1% 66 - 78,6% 
Y 63 - 13,9% 16 - 19% 
Mortality N 159 - 35,1% 47 - 55,9% 
Y 294 - 64,9% 35 - 41,7% 
Missing value 0 - 0% 2 - 2,4% 
 
• Missing data were excluded from percentage 
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Table 2: Co-morbidities and Diagnostics for ALPPS patients 
Variable Categorization All patients = 86 
• BMI  25,3 (16,3-38,3) 
• DM Yes 10/84 – 11,9% 
• Other Comorbidities Yes 12/86 – 13,9% 
• Previous Major 
Surgery 
Yes 1/86 – 1,2% 
• Neoadjuvant CTH Yes 7/85 – 8,1% 
• Previous radiology 
intervention 
Yes 4/82 – 4,9% 
• Tumor Location 
single lesion centrally located 60/82 – 73,2% 
multiple tumors located in right liver lobe 
requiring extended right hepatectomy 16/82 – 19,5% 
Bilobar tumors requiring clearance of FLR and 
right or extended right hepatectomy 6/82 – 7,3% 
• Surgeon Decision 
neither volume nor function of FLR is sufficient 81/83 – 98,6% 
volume enough but functional FLR is not 
sufficient 2/83 – 2,4% 
• Missing data were excluded from percentage 
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• (4.2) procedure details: 
a. Stage-1 Hepatectomy 
About 18.8% of the patients (n=16) received blood transfusion during the 
operation. Lymphadenectomy was performed in 64.2% of the patients (n=52/81) 
The duration between the 2 stages was ranging from 3 to 49 days (median value 
= 11 days) and the average post-operative intensive care unit (ICU) admission 
ranged from 0 to 13 days (mean = 1 day).  
b. Stage-2 Hepatectomy 
About 30.3% of the patients (n=20) received blood transfusion during the 
second operation. Lymphadenectomy was performed in 23.4% of the patients 
(n=18). The average post-operative ICU admission ranged from 0 to 40 days 
(median value = 1 day). 
 
Table. 3: Procedure Details 
1st stage Hepatectomy 
Variable All patients = 86 
Days between 1st and 2nd stage 11 (3-49) 
RBC transfusion 16/85 – 18,8% 
 Lymphadenectomy performed 52/81 – 64,2% 
PO ICU days 1 (0-13) 
2nd stage Hepatectomy 
Variable All patients = 84 
Days between 1st and 2nd stage 11 (3-49) 
RBC transfusion 20/66 – 30,3% 
 Lymphadenectomy performed 18/77 – 23,4% 
PO ICU days 1 (0-40) 
• Missing data were excluded from percentage 
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•  (4.3) Volumetry Study Results 
The median FLR volume before stage one operation was 328 ml (128-664). 
The median FLR/ body weight (BW) ratio of stage one operation was 0.46 (0.19-
0.84). The median FLR volume before stage two was 547 ml (270-933 ml). The 
FLR/ body weight (BW) ratio ranged from 0.35 to 1.51 (median = 0.84). The 
Delta FLR between the first and second operations ranged from 13 ml to 504 ml 
(median= 234 ml). Delta FLR/BW ratio ranged from 0.02 to 0.94 (median=0.32). 
(Table 4) 
 
 
 
 
 
Table. 4: Volumetry study 
Variabile Values 
FLR stage 1 328 (128-664).  ml 
FLR/BW stage 1 0.46 (0.19-0.84). 
FLR stage 2 574 (270 – 933). ml 
FLR/BW stage 2 0,84 (0.35-1.51) 
Delta FLR stage 1-2 234 (13-504). ml 
Delta FLR/BW ratio stage 1-2 0.32 (0.02-0.94) 
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• (4.4) Histopathology Assessment.  
Among studied population, adenocarcinoma was reported in 91.5% 
(n=75). Negative margin was achieved in 86.4% (n=70). Based on the 7th 
edition of AJCC staging system, stage I was reported in 7.8% (n=6), stage II 
in 41% (n=33), stage III in 8.7% (n=7) and stage IVa reported in 42.5% 
(n=34). Lymph node was positive in 40.7% (n=33). Multifocality was reported 
in 39,8% (n=33). According to degree of differentiation; well differentiated 
tumor (Grade I) was reported in about 8% of the patients (n= 6) while 
moderate differentiated (Grade II) was seen in 56% (n=43). Poor 
differentiation was reported in 36% (n=34). Normal liver parenchyma was 
documented in 62.5% (n=45). A Detailed list of histo-pathological features is 
shown in Table no. 5. 
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Table. 5: Histopathology assessment 
Variable Definition Number and Percentage All patients = 84 
Histology Adenocarcinoma 75/82 – 91,5% Other 7/82 – 8,5% 
Margin negative of tumor 70/81 – 86,4% positive of tumor 11/81 – 13,6% 
Grading 
I 6/77 – 7,8% 
II 43/77 – 55,8% 
III 28/77 – 36,4% 
Stage 7th edition AJCC 
I  6/80 – 7,8% 
II  33/80 – 41,2% 
III  7/80 – 8,7% 
IVa  34/80 – 42,5% 
T 7th edition AJCC 
T1 9/80 – 11,2% 
T2 35/80 – 43,7% 
T2a 6/80 – 7,8% 
T2b 14/80 – 17,5% 
T3 15/80 – 18,7% 
T4 1/80 – 1,1% 
N N0 48/81 – 59,3% N1 33/81 – 40,7% 
Metastasis M0 83/83 – 97,6% M1 0/83 – 2,4% 
Multifocal lesion N 50/83 – 60,2% Y 33/83 – 39,8% 
Largest tumor size (mm)  85 (6-260) 
Liver Parenchyma status 
Normal 45/72 – 62,5% 
Fibrosis 17/72 – 23,1% 
Steatosis more than 30%  6/72 – 8,3% 
CASH  3/72 – 4,2% 
Cirrhosis 1/72 – 1,9% 
• Missing data were excluded from percentage 
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• (4.5) Survival analysis and Recurrence: 
a) Before propensity score analysis: 
For ALPPS group (n= 82), the median follow-up was 10.7 months (0-36). The 
median overall survival (OS) was 27.6 months. The 1,2,3-year survival rates were 
67,8%, 60.3% and 41%. For CTH group (n=453), the median follow-up was 8 
months (0-36). The median OS was 10 months. The 1,2,3-year survival rates were 
43,8%, 18.3% and 5.6%. (p value < 0.001- table 6 and fig. 1). After exclusion the 
90-day mortality from the analysis, survival rates were superior in ALPPS group 
in comparison to CTH group. (table 7 and fig. 2). 
b) After propensity score analysis: 
 For ALPPS group (n=79), the median OS was 27.6 months. The 1,2,3-year 
survival rates were 68,1%, 60.1% and 40.8%. For matched group of CTH patients 
(n=79), the median OS was 12 months. The 1,2,3-year survival rates were 49,7%, 
18.4% and 9.2%. (p value < 0.004- table 8 and fig. 3). After exclusion the 90-day 
mortality from the analysis, survival rates and OS were superior in ALPPS group 
in comparison to CTH group. (table 9 and fig. 4). 
 During study period recurrence rate was 57.5% (n=46/80). Hepatic 
recurrence rate was reported in 48.7% (n=37) while extrahepatic recurrence was 
detected in 32.4% (n=23). The risk of local or extrahepatic recurrence after liver 
resection was 61%, 75% and 86% for the 1st, 2nd and 3rd year respectively. The 
median time to recurrence was 8.2 months ranging from 6.4 to 10 months as 
documented in tables 10a-c and figures 5a-c.   
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Figure 1: OS in all patients before PS 
Figure 2: OS before PS after exclusion 
90-Day mortality patients. 
 
a 
 
 
 
  
 Table.6 Survival Rates before propensity analysis 
All patients CTH Group (453) ALPPS Group (82) 
1yr 43,80% 67,80% 
2yr 18,30% 60,30% 
3yr 5,60% 41,00% 
Median OS 10,00 27,60 
Median FU 8 (0-36) 10,7 (0-36) 
p value <0,001 
 Table.7 Survival Rates before propensity analysis 
90-Day mortality nor included 
 CTH Group (390) ALPPS Group (66) 
1yr 51,20% 84,70% 
2yr 21,40% 75,30% 
3yr 6,60% 51,20% 
Median OS 13,00 - 
p value <0,001 
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Figure 3: OS in all patients after PS 
Figure 4: OS in after PS after  exclusion 
90-Day mortality patients  
a 
  
Table.8 Survival Rates after propensity analysis 
All patients CTH Group (79) ALPPS Group (79) 
1yr 49,70% 68,10% 
2yr 18,40% 60,10% 
3yr 9,20% 40,80% 
Median OS 12,00 27,60 
p value 0,004 
Table.9 Survival Rates after propensity analysis 
90-Day mortality nor included 
 CTH Group (73) ALPPS Group (63) 
1yr 53.90% 85.90% 
2yr 20.00% 75.80% 
3yr 10.00% 51.50% 
Median OS 14.00 - 
p value <0,001 
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Table 10a: Risk of recurrence Intrahepatic 
year ALPPS Group (76) 
1yr 54.9% 
2yr 68.3% 
3yr 78.2% 
Time to Recurrence 9,4 (5,2-13,5) 
Table 10b: Risk of recurrence Extrahepatic 
year ALPPS Group (71) 
1yr 31.2% 
2yr 46.6% 
3yr 52.6% 
Time to Recurrence 31.4 (13,3-36) 
Table 10c: Risk of recurrence any where 
year ALPPS Group (71) 
1yr 61% 
2yr 75% 
3yr 86.7% 
Time to Recurrence 8.2 (6.4-10) 
Figure 5a: Risk of recurrence Intrahepatic 
Figure 5b: Risk of recurrence Extrahepatic 
Figure 5c: Risk of recurrence Intrahepatic 
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• (4.6) Overall survival prognostic factors: 
In order to identify prognostic factors, those independently affect survival, 
univariate then multivariate COX regression survival analyses were performed.  
a) Univariate COX regression analysis (table.11A): 
Poor prognosis has been reported in male patients (p=0.02, HR=2.2, 95% CI), 
above 60 (p=0.04, HR=2.3, CI 95%), with ICU admission > one day post-
operative stage-1 (p=0.05, HR=1.9, CI 95%). Factors related to post stage-2 
operation with poorer prognosis were; post-operative ascites (p=0.065, HR= 2.2, 
CI 95%), infection (p=0.04, HR= 2.0, CI 95%) and / or complications classified 
as Dindo-Clavien ≥ 3b (p=0.03, HR= 2.0, CI 95%). Lymph node metastasis was 
the only reported pathological feature with a poor prognosis (p=0.01, HR=2.4, CI 
95%). 
b) Multivariate COX regression analysis (table.11B): 
 In multivariate module, poor prognosis has been reported for cases 
developing infection post 2nd stage hepatectomy (p=0.03, HR=2.1, CI= 95%) 
and/or positive lymph node metastasis (p=0.007, HR=2.7, CI95%). All other 
considered covariables were statistically not significant. 
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Table. 11: Univariate and Multivariate COX regression for overall survival 
A. Univariate analysis 
Demogarphics pre-operative and Variables P value HR 95% CI 
Age ,005 1,061 1,018 1,105 
AGE > 60 ,041 2,371 1,036 5,428 
AGE > 65 ,129 1,678 ,860 3,273 
Gender: Male ,023 2,200 1,116 4,336 
BMI ,651 ,982 ,910 1,061 
BMI>25 ,575 1,212 ,620 2,370 
BMI>30 ,198 ,459 ,140 1,502 
*ASA>3 ,123 1,813 ,850 3,865 
Co-morbidity (Y) ,666 1,190 ,541 2,615 
DM (Y) ,967 1,022 ,361 2,893 
Neoadjuvant_Chemotherapy (Y) ,580 ,668 ,160 2,786 
Preoperative radiological intervention (Y) ,340 ,380 ,052 2,779 
Tumor distribution single centrally located lesion (Baseline) ,427 
   
Tumor distribution: Multifcoal in Rt lobe ,202 1,652 ,764 3,574 
Tumor distribution: Biloblar, Multifocal ,597 1,333 ,458 3,878 
Stage-1 Variabels P value HR CI 95% 
Stage_1_RBC_transfusion(Y) ,874 1,066 ,485 2,343 
lymphadenectomy_Stage_1(Y) ,414 1,360 ,650 2,845 
**Post_stage1_Intensice Care Unit/days ,004 1,208 1,063 1,373 
Post_stage1_Intensice Care Unit/days >1 ,051 1,923 ,996 3,714 
Liver Failure Stage 1 (Y) ,969 1,021 ,355 2,935 
Ascites Stage-1 (Y) ,707 1,228 0,421 3,588 
Haemorrhage Stage 1 (Y) ,361 ,661 ,273 1,604 
Infection Stage 1 (Y) ,204 1,777 ,732 4,316 
Biliary complications Stage-1 (Y) ,138 ,407 ,124 1,336 
Dindo-Clavien Stage 1≥3a ,477 1,377 ,570 3,325 
Dindo-Clavien 1≥3b ,990 ,987 ,134 7,257 
Days_between_1st_and_2nd_stage_operation ,544 1,013 ,971 1,058 
Days_between_1st_and_2nd_stage_operation>11 ,414 1,320 ,678 2,570 
Stage-2 Variabels P value HR CI 95% 
Post_stage_2_Intensice Care Unit_days ,000 1,075 1,033 1,119 
Post_stage_2_Intensice Care Unit_days>1 ,259 1,483 ,748 2,938 
Stage_2_op_RBCs_Transfusion(Y) ,268 1,567 ,708 3,469 
Stage_2_lymphadenectomy(Y) ,545 ,744 ,285 1,943 
Liver Failure Stage 2 (Y) ,613 1,212 ,576 2,550 
Ascites Stage-2 (Y) ,065 2,257 ,950 5,364 
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Haemorrhage Stage 2 (Y) ,364 1,387 ,684 2,814 
Infection Stage 2 (Y) ,040 2,029 1,031 3,992 
Biliary complications Stage 2 (Y) ,600 ,825 ,403 1,689 
Dindo-Clavien Stage 2≥3a ,110 1,739 ,882 3,429 
Dindo-Clavien Stage 2≥3b ,038 2,035 1,039 3,986 
Volumetry study Variabels P value HR CI 95% 
FLR_clean_stage_1 ,882 1,000 ,997 1,003 
FLR/BW_stage_1 ,735 ,658 ,058 7,429 
FLR/BW_stage_1>0,46  ,857 1,070 0,514 2,225 
FLR_stage_2 ,390 ,999 ,997 1,001 
FLR/BW_stage_2 ,265 ,427 ,096 1,905 
FLR/BW_stage_2>0,84,  ,417 0,755 0,383 1,488 
Pathological features Variabels P value HR CI 95% 
Margin positive of tumor ,496 ,718 ,276 1,866 
Grading G1 (Baseline) ,351       
Grading G2 ,244 ,521 ,174 1,562 
Grading G3 ,699 ,800 ,259 2,475 
AJCC 7th Stage I (Baseline) ,063       
AJCC 7th Stage II ,362 ,550 ,152 1,988 
AJCC 7th Stage III ,394 ,457 ,075 2,769 
AJCC 7th Stage IVA ,540 1,467 ,430 5,003 
T1 (Baseline) ,951       
T2 ,580 1,405 ,421 4,684 
T3 ,597 1,441 ,372 5,584 
T4 ,703 1,558 ,160 15,163 
N1 ,011 2,453 1,228 4,900 
Multifocal lesion (Y) ,700 1,142 ,583 2,237 
Largest_tumor_size_mm ,337 1,004 ,996 1,012 
Largest_tumor_size>85 ,170 1,606 ,816 3,162 
liver parenchyma histology result - Not normal ,608 1,213 0,58 2,538 
B. Multivariate Analysis 
Variabels P value HR 95% CI 
Infection Stage 2 (Y) 0,039 2,134 1,038 4,388 
Dindo-Clavien Stage 2≥3b 0,173 1,636 0,806 3,319 
N1 0,007 2,724 1,312 5,652 
 *ASA: American Society of Anesthesiologists score,  
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• (4.7) Post-operative Complications (table.12-Fig.6) 
a) Post Stage-1 Hepatectomy 
According Dindo-Clavien classification; 8.5% of the patients had score 
=3a (n= 7/82), while only 4.9% (n=4/81) had Dindo-Clavien score ≥ 3b. No 
mortality was reported after stage 1. More details are shown in table 12. 
b) Post Stage-2 Hepatectomy 
According Dindo-Clavien classification; 18.5% of the patients had Dindo-
Clavien score = 3a (n=15/81), score while 34.5% had Dindo-Clavien score ≥ 3b 
(n=28/81). According to ISLGS grading system 13.4 % of the patients (n=9/67) 
have developed PHLF classified as grade C. 27.3% of the patients (n=15) has 
developed ascites > 1000ml/ day after day-7 which required medical treatment. 
Sever infection classified as Dindo-Clavien grade IIIb was reported in 9% 
(n=7/77). 13% of the patients has a reported infection with no further details 
revealed (n=10). Biliary leakage reported in 9 % of the patients which is classified 
as grade C according to ISLGS grading system (n=7). 12.8% of the patients 
developed biliary complications with no further details revealed. PHH that 
require re-operation has been reported in 3 patients only. 
During the study period, mortality rate was reported in 43% of the studied 
population. 90-day mortality rate was reported in 19% of the cases (n= 16). 90-D 
mortality rates / year were 30%, 38% and 9% in 2013, 2015 and 2017 
respectively. (Fig. 6) 
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Table. 12: Post-operative Complications (stage1-2) 
Complications Grade Definition (ISGLS or Dindo-Clavien) 
Post stage-1 
patients = 86 
Post stage-2 
patients =84 
Liver Failure 
(ISLGS grade)  
No Reported PHLF 59/67 – 88,1% 43/67 – 64,2% 
Grade A (Elevated bilirubin and INR, no treatment) 06/67 – 8,9% 08/67– 11,9% 
Grade B (infusion of albumin, FFP) 02/67 – 3% 09/67 – 13,4% 
Grade C (ICU treatment or surgery) 00/67 – 0% 07/67 – 10,5% 
Ascites   
Not reported or less than 500 ml 51/60 – 85% 28/55 – 50,9% 
over 500 ml without medical treatment 06/60 – 10% 06/55 – 10,9% 
less than1000 ml after day 7 with medical treatment 01/60 – 1,7% 06/55 – 10,9% 
more than 1000 ml after day 7 with medical treatment  02/60 – 3,3% 15/55 – 27,3% 
reported as ascites with no further detail 0/60 – 0% 0/55 – 0% 
Haemorrhage 
(ISGLS grade)  
No transfusion required 59/78 – 75,6% 52/77 – 67,5% 
Grade A: transfusion up to 2 Units of RBC 04/78 – 5,1% 06/77 – 7,8% 
Grade B: transfusion more than 2 Units of RBC 02/78 – 2,6% 04/77 – 5,2% 
Grade C: intervention or reoperation 01/78 – 1,3% 03/77 – 3,9% 
reported as haemorrhage with no further detail 12/78 – 15,4% 12/77 – 15,6% 
Infection 
(Dindo-Clavien) 
No Reported infection 68/77 – 88,3% 49/77 – 63,6% 
Grade II Dindo-Clavien (medications) 08/77 – 10,4% 07/77 – 9,1% 
Grade IIIa (interventional) 01/77 – 1,3% 04/77 – 5,2% 
Grade IIIb and more (re-OP or ICU) 00-/77– 0% 07/77 – 9,1% 
reported as infection with no further detail 00/77 – 0% 10/77 – 13% 
Biliary Leakage 
(ISGLS grade)  
No reported leakage 69/79 – 87,4% 50/78 – 64,1% 
grade A (observation till day 7 with existing drainage 07/79 – 8,9% 04/78 – 5,1% 
grade B (leak more than 7 days or needs intervention) 03/79 – 37% 07/78 – 9% 
grade C (re-operation, or ICU) 00/79 – 0% 07/78 – 9% 
reported as biliary complication with no further detail 00/79 – 0% 10/78 – 12,8% 
• Missing data were excluded from percentage 
• Some complications were reported as Dindo-Clavien ≥ 3b without further details. 
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Figure 6: Morbidity and 90-day mortality rates / year 
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• (4.8) Risk Factors for Severe Complications (Clavien-Dindo ≥3B) 
To verify risk factors for complications graded as Clavien-Dindo ≥3b, 
univariate and multivariate logistic regression analyses has been conducted to the 
parameters demonstrated in table 13.  
a) Univariate logistic regression: (Table 13) 
Statistically significant risk factors were; age > 65 years (p=0.005, ODDS 
=3.9, CI95%), blood transfusion during 1st stage operation (p=0.09, ODDS=2.6, 
CI 95%), PHH stage-1(p= 0.09, ODDS=2.5, CI 95%) and/ or prolonged ICU 
admission >1day post stage-1 (p=0.08, ODDS=2.2, CI 95%). 
Risk factors related to 2nd stage hepatectomy were; prolonged ICU admission 
>1day (p=0.01, ODDS=2.5, CI 95%), PHH (p=0.001, ODDS=5.9, CI 95%), 
PHLF (p=0.04, ODDS=2.9, CI 95%), post stage-2 infection (p=0.0031, 
ODDS=4.5, CI 95%).  
Patients with; FLR/BW>0,46 post stage-1(p=0.05, ODDS=0.3, CI 95%) 
and/or FLR/BW>0,84 post stage-2 (p=0.01, ODDS=0.2, CI 95%) are less likely 
to develop sever complications. 
b) multivariate logistic regression analysis: (table. 13B) 
A patient age > 65 years old (p=0.03, ODDS =3.9) and post stage-2 
infection (p=0.049, ODDS=3.1) were statistically significant risk factors. 
Patients with FLR/BW>0,46 post stage-1 (p=0.09, ODDS=.03) are less likely to 
develop sever complications by multivariate logistic.  
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Table 13:  Univariate and Multivariate Logistic Regression for Dindo-Clavien ≥3b 
 A- UNIVARIAT ANALYSIS for Dindo-Clavien ≥3b 
Demogarphics and co-morbidity Variabels p value ODDS 95% CI 
Age ,009 1,073 1,018 1,131 
AGE>65 ,005 3,977 1,513 10,453 
Male ,119 2,083 ,827 5,248 
BMI ,540 1,035 ,926 1,157 
BMI>25 ,542 1,333 ,529 3,363 
BMI>30 ,361 1,753 ,526 5,843 
*ASA score>3 ,391 1,571 ,559 4,414 
Comorbidity (Y) ,878 1,087 ,374 3,158 
DM (Y) ,792 1,200 ,309 4,658 
Neoadjuvant CTH(Y) ,728 ,738 ,134 4,074 
Pre-operative radiology intervention(Y) ,562 1,815 ,242 13,619 
Stage-1 Variabels P value ODDS 95% CI 
Stage_1_RBC_transfusion(Y) ,097 2,629 ,839 8,237 
lymphadenectomy_Stage_1(Y) ,402 ,667 ,258 1,721 
Post_stage1_Intensive Care Unit admission_ days ,017 1,293 1,046 1,599 
Post_stage1_Intensive Care Unit admission_ days>1 ,086 2,256 ,890 5,720 
PHLF Stage 1 (Y) ,841 1,170 ,253 5,401 
Ascites Stage 1 (Y) 1,000 1,000 ,222 4,496 
Post hepatectomy haemorrhage Stage 1 (Y) ,094 2,562 ,851 7,713 
Infection Stage 1 (Y) ,501 1,558 ,429 5,662 
Biliary complications Stage 1 (Y) ,262 ,394 ,078 2,003 
Days_between_1st_and_2nd_stage_operation ,428 1,022 ,968 1,079 
Days_between_1st_and_2nd_stage_operation>11days ,387 1,498 ,599 3,746 
Stage-2 Variabels P value ODDS 95% CI 
Post_stage_2_ Intensive Care Unit admission _days ,016 1,192 1,033 1,376 
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Post_stage_2_ Intensive Care Unit admission _days>1 ,055 2,595 ,982 6,858 
Stage_2_op_RBCs_Transfusion(Y) ,257 1,870 ,634 5,517 
Stage_2_lymphadenectomy(Y) ,417 1,560 ,533 4,569 
PHLF Stage 2 (Y) ,047 2,909 1,015 8,341 
Ascites Stage 2 (Y) ,337 1,765 ,554 5,620 
PHH Stage 2 (Y) ,001 5,926 2,093 16,778 
Infection Stage 2 (Y) ,003 4,500 1,671 12,120 
Biliary complications Stage 2 (Y) ,150 2,022 ,776 5,270 
Other Variabels P value ODDS 95% CI 
FLRBW_stage_1>0,46 ,055 0,362 0,128 1,021 
FLRBW_stage_2>0,84 ,015 0,287 0,105 0,783 
liver parenchyma histology result – diseased parenchyma ,513 1,403 0,509 3,869 
B- MULTIVARIAT ANALYSIS for Dindo-Clavien ≥3b 
Variabels p value ODDS 95% CI 
AGE>65 ,030 3,900 1,145 13,286 
Infection Stage 2 (Y) ,049 3,182 1,005 10,079 
FLRBW_stage_1>0,46 ,094 ,352 ,104 1,194 
 
 *ASA: American Society of Anesthesiologists  
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• (4.9) Risk factors for 90-day mortality (table.14): 
To verify significant risk factors for 90-day mortality, univariate logistic 
regression has been performed considering the parameters demonstrated in table 
14. Statistical significant factors were; male gender (p=0.05, ODDS=3.0, 
CI=95%), age above 65 (p=0.1, ODDS=4.5, CI=95%) and/or prolonged ICU 
admission> one day post stage-1 (p=0.01, ODDS= 4.4, CI 95%).  
Other significant risk factors related to 2nd stage hepatectomy were; 
prolonged ICU admission >1day (p=0.01, ODDS=6, CI 95%), PHH (p=0.06, 
ODDS=3.0, CI 95%), PHLF (p=0.03, ODDS=3.8, CI 95%), post-operative 
ascites (p=0.07, ODDS=4.5, CI 95%) and/or complications classified as Dindo-
Clavien ≥3b (p=0.01, ODDS=4.3, CI 95%) or as Dindo-Clavien ≥3a (p=0.01, 
ODDS=5.0, CI 95%). All other considered covariables were not statistically 
significant. 
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 Table 14: UNIVARIATE LOGISTIC REGRESSION 90-Day Mortality  
Demogarphics and co-morbidities Variabels p value ODDS 95% CI 
AGE>65 0,016 4,556 1,330 15,608 
M 0,052 3,056 0,989 9,437 
BMI>25 0,983 1,012 0,329 3,114 
*ASA>3 0,513 1,474 0,461 4,712 
Comorbidity (Y) 0,800 1,178 0,331 4,188 
DM (Y) 0,967 1,036 0,198 5,424 
Neoadjuvant CTH(Y) 0,728 ,678 0,076 6,063 
Stage-1 Variabels p value ODDS 95% CI 
Stage_1_RBC_transfusion(Y) 0,464 ,551 0,112 2,713 
lymphadenectomy_Stage_1(Y) 0,738 ,821 0,260 2,598 
PO_stage1_ICU_days 0,010 1,349 1,073 1,696 
PO_stage1_ICU_days>1 0,013 4,400 1,359 14,241 
Liver Failure Stage 1 (Y) 0,603 ,560 0,063 4,995 
Ascites Stage 1 (Y) 0,744 1,333 0,237 7,510 
Haemorrhage Stage 1 (Y) 0,316 ,442 0,090 2,177 
Infection Stage 1 (Y) 0,947 1,058 0,200 5,581 
Biliary complications Stage 1 (Y) 0,999 ,000 0,000  
C-D Stage 1≥3a 0,469 ,452 0,053 3,872 
C-D Stage 1≥3b 0,512 2,286 0,194 26,999 
Days_between_1st_and_2nd_stage_operation 0,838 ,993 0,926 1,065 
Days_between_1st_and_2nd_stage_operation>11days 0,577 1,369 0,454 4,123 
Stage-2 Variabels p value ODDS 95% CI 
Post_stage_2_ICU_days 0,003 1,280 1,087 1,508 
Post_stage_2_ICU_days>1 0,010 6,000 1,530 23,530 
Stage_2_op_RBCs_Transfusion(Y) 0,348 1,857 0,510 6,766 
Stage_2_lymphadenectomy(Y) 0,731 ,783 0,195 3,152 
Liver Failure Stage 2 (Y) 0,038 3,800 1,077 13,408 
Ascites Stage 2 (Y) 0,076 4,550 0,851 24,318 
Haemorrhage Stage 2 (Y) 0,061 3,025 0,951 9,628 
Infection Stage 2 (Y) 0,113 2,543 0,802 8,068 
Biliary complications Stage 2 (Y) 0,881 1,091 0,350 3,404 
Dindo-Clavien Stage 2≥3a 0,018 5,056 1,315 19,439 
Dindo-Clavien Stage 2≥3b 0,012 4,352 1,380 13,726 
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Volumetry Variabels p value ODDS 95% CI 
FLR/BW_stage_1>0,46 0,631 ,729 0,201 2,651 
FLR/BW_stage_2>0,84 0,205 ,460 0,139 1,527 
Pathological features p value ODDS 95% CI 
Multifoca lesion (Y) 0,978 ,984 0,319 3,039 
Largest_tumor_size>85 mm 0,500 1,463 0,484 4,424 
Margin positive of tumor 0,348 ,360 0,043 3,041 
liver parenchyma histology result- diseased parenchyma 0,506 1,510 0,448 5,089 
Grading G1 (Baseline) 0,344    
Grading G2 0,877 ,833 0,082 8,433 
Grading G3 0,554 2,000 0,201 19,914 
AJCC 7th Stage I (Baseline) 0,460    
AJCC 7th Stage II 0,760 ,690 0,063 7,512 
AJCC 7th Stage III 0,615 2,000 0,134 29,808 
AJCC 7th Stage IVA 0,589 1,875 0,192 18,324 
T1 (Baseline) 0,743    
T2 0,456 2,286 0,260 20,131 
T3T4 0,621 1,846 0,163 20,939 
N1 0,144 2,292 0,754 6,968 
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Discussion: 
The majority of patients with intrahepatic cholangiocarcinoma present in 
an advanced unresectable stage with limited treatment options.  These patients 
who do not qualify for surgery usually undergo palliative systemic 
chemotherapy.7,49 Currently, the gold standard for advanced biliary tumors 
consists of a combination of gemcitabine plus cisplatin, which offers a modest 
survival over gemcitabine monotherapy (11.7 vs 8.1 months, respectively). Other 
gemcitabine-based regimens, notably gemcitabine plus oxaliplatin, have shown 
similar efficacy.73,74  
Other published data showed that combined systemic and hepatic arterial 
infusion chemotherapy treatment is associated with better prognosis, superior 
response and overall survival than systemic chemotherapy alone. The median 
overall survival for the study cohort for patients with locally advance or nodal 
disease was 17.1 months (range: 1.4–58.9 months).75  
Other alternative approaches are loco-regional treatment such as 
radiofrequency (RFA) and microwave ablation (MWA). These approaches are 
frequently applied with small localized unresectable tumors, recurrence or 
residual tumor after surgery. However, few studies suggested that RFA may have 
survival benefits when compared with other palliative treatment methods in 
patients with small, single unresectable IC lesions with no distant metastasis.76-79  
Despite of the availability of modern treatments for IC, curative resection 
remains the treatment of choice which offers a chance for long term survival; 
resulting in a median survival ranging from 27 to 36 months. However, the safe 
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removal of large amount of liver parenchyma is still a challenge in HPB surgery. 
The majority of IC cases presented in advanced stages at time of diagnosis which 
require extensive liver resection and so high risk to develop PHLF due to low 
FLR. 45-50  
Recently, Schnitzbauer et al. has introduced ALPPS approach to enable 
curative resection for advanced liver tumors. It was literally described as “one of 
the most promising advances in modern oncological liver surgery” not only by 
making marginal irresectable lesions resectable, but also its exceptional results of 
surgically induced, fast liver hypertrophy .61,62  
A definitive evidence for long term benefit in terms of survival and 
oncological outcome of ALPPS procedure for IC is still lacking. Currently, there 
is no large comparative study available to evaluate the cost-benefit ratio of 
ALPPS procedure in comparison to routinely offered palliative chemotherapy. 
Another vital criticism has been conducted to ALPPS procedure due to relatively 
high morbidity and mortality. Particularly in primary liver tumors, authors 
recommended not perform this approach outside studies and registries.80 
Herby, we sought to investigate the long-term outcome of ALPPS 
procedure for Intrahepatic cholangiocarcinoma patients as regard the overall 
survival, oncological outcome highlighting morbidities and 90-day mortality.  
The message we wanted to verify by this study is, whether surgeons could keep 
performing ALPPS for IC, due to its long-term survival benefits, with strict risk 
adjustments to avoid unfavorable outcome or shall this procedure be restricted 
due to its inevitable overwhelming morbidities and mortalities.  
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The results of our comparative survival analysis provide a strong evidence 
for superior long-term outcome of ALPPS procedure over palliative 
chemotherapy. Despite of its relatively high 90-day mortality, ALPPS has shown 
a better 3 years survival rates which has been reconfirmed by propensity score 
analysis as well (Fig.1-4). Therefore, we believe that extensive liver resection by 
ALPPS procedure could provide a better chance of cure for this high-risk 
population with locally advanced IC lesions, who usually offered palliative 
chemotherapy. 
Indeed, the 90-day mortality of 19% in our study is undoubtedly high in 
comparison with mortality rate for conventional hepatectomies or ALPPS 
performed for colorectal liver metastasis.65 We would like to underline that, the 
reported results of early mortality in our cohort represent both the initial and the 
recent experiences. The 90-day mortality for ALPPS procedure performed for IC 
in 2106 and 2017 was 9% (n=1/11). While the 90-day mortality rates were 14% 
(n=2/14) in 2012, 30% (n=3/10) in 2013, 15% (n=3/20) in 2014 and 38% 
(n=5/13) in 2015 (2/12) in 2016 (Fig6). We claim that; the inherited learning 
curve would inversely proportionate to morbidity and mortality rates and a better 
outcome will be achieved by time.  
Obviously, achieving complete tumor resection (R0 in 86.4%) in this study 
was on the cost of post-operative morbidity and mortality. In our cohort study, 
34.6% of the patients suffered from severe complication which demanded 
intervention under general Anesthesia (Dindo-Clavien >3b).  
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Similar to conventional liver surgery results, 81 the main causes for severe 
complications in ALPPS group were, abdominal sepsis, biliary leakage and 
PHLF. (table. 12) 
There is no doubt that, achieving R0 would result in better long term 
oncological outcome. 44,45 However, the risk to develop post-operative morbidity 
and mortality in ALPPS procedure with R0 resection should be weighed against 
the hazard of incomplete resection (R1) using conventional approach. Decision 
making remains in some cases a major challenge as the post-operative course and 
the procedure outcome are -to some extent- unpredictable and ambiguous even in 
highly specialized centers. In addition, it is not yet well understood how to 
objectively define the acceptable morbidity mortality rates for such advanced 
malignancies in correlation to the curative potentiality of this surgical approach. 
The cumulative experiences of this procedure have led to risk adjustments’ 
maneuvers which resulted in significant improvements in the surgical technique 
and better decisions as regard patients’ selection and management.82 For example, 
some authors have considered cholestatic liver underwent ERCP or PTC as a 
contraindication for ALPPS due to unacceptable rates of biliary and septic 
complications.83  
Additional to that, a new concept of incomplete liver resection in stage-1 
hepatectomy known as partial ALPPS was proposed to reduce the risk of inter-
stage complications as biliary leakage and liver ischemia.84,85 These refinements 
will eventually lead to acceptable rates of morbidities, mortalities and will result 
in more convincing short and long-term surgical outcomes.  
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To reach the standard outcome for conventional major hepatectomies, 
some authors have hypothetically proposed the following recommendations:80 
1. Patients should be clearly informed about the higher risk to develop 
perioperative morbidity and early mortality through an informed consent. 
2. The procedure should be performed in highly specialized centers by the 
expertise in complex liver surgery. 
3. ALPPS approach is preferentially performed in the setting of large tumor 
load with marginal FLR with curative intent. 
4. Should be used with caution in patients older than 70 years and/or with 
primary liver tumors (HCC, CCC). 
5. Concomitant major abdominal surgery should be avoided. 
6. Sharing experiences and knowledge through registration of patients in the 
international registry (www.alpps.net)  
The main limitation of this study attributed to its retrospective methodology 
nature which leads to selection bias in both groups. A randomized control trial to 
investigate short and long-term outcomes would provide a more reliable results. 
Another limitation of the study conducted to the missing values and unshared 
informations of the procedure e.g. some operative details regarding technical 
variations, perioperative laboratory findings… etc. Completeness of the data will 
result in better stratification of the patients which will help to accurately define 
the significant risk factors and to identify the sub-group of patients who are 
vulnerable to develop sever post-operative complications or in-hospital mortality. 
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We have utilized the AJCC staging system, 7th edition in our analysis which 
is the same edition utilized in both ALPPS and SEER database. Recently, the 
AJCC has released a new staging system for IC in its 8th edition. Nevertheless, 
Pawlik et al. reported that 8th edition staging system for IC has not shown a 
significant privilege over 7th edition in the overall prognostic discrimination 
except for stage III which represent only 8.7% of our patients. 31 
From another aspect, a major advantage of this study is utilizing ALPPS 
registry-database as a baseline to create an international ALPPS prospective 
cohort with a longitudinal study design by retrieving new data on ALPPS 
approach not reported by the registry web site.  This advantage will facilitate 
establishment further studies to investigate more detailed long-term oncological 
outcome of ALPPS procedure and risk adjustments analyses as well. However, 
further work is needed to achieve a significant improvement in the completeness 
and the quality of the data. Therefore, we urge all expertise to share their 
experiences and data through registration to ALPPS registry. (www.alpps.net) 
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Conclusion: 
Despite of its relatively high morbidity and early mortality; ALPPS 
approach shows remarkable superior results in overall survival analysis compared 
to palliative chemotherapy for Intrahepatic cholangiocarcinoma patients. More 
strict risk adjustments are mandatory to avoid post-operative morbidity and 
mortality. Further studies are needed to identify the subgroup of IC patients who 
would potentially benefit from the procedure with acceptable morbidities and 
negligible early postoperative mortality. 
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